Manufacturers withdraw US market authorisation for atezolizumab for prior-platinum treated metastatic urothelial carcinoma

The FDA had previously grated accelerated approval for this indication based on the results from the IMvigor210 study, however a post marketing study did not meet its primary endpoint of overall survival in the PD-L1 high patient population.

PharmaTimes